Drug Trial Radar · NCT06468033
P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk
Last checked: Nov 20, 2026Latest source record: Aug 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
160
Actual
Start
Jul 18, 2025
Primary completion
Nov 18, 2027
Study completion Jan 11, 2029
Sponsor
- Lead sponsor
- PharmaEssentiaIndustry
- Sponsor type
- Industry
- First posted
- Jun 21, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase 3 double-blind clinical trial arm to test Ropeginterferon alfa-2b (P1101) in adult patients with Primary Myelofibrosis (PMF) at early stage or low to medium risk. Participants will receive the study drug/placebo bi-weekly and have an assessment visit every 4 weeks. The ratio of study drug to placebo group is 2:1.
Conditions
- Primary Myelofibrosis
- Myeloproliferative Neoplasm
Interventions
Ropeginterferon alfa-2bBiological
Pre-filled Syringe. Dosage: up to 500mcg
PlaceboOther
Placebo is a look-alike substance with the intervention (Ropeginterferon alfa-2b) that contains no active drug.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Platelet count equal or less (≤) 400 × 10^9/LTime frame: 80 weeks
- Number of Participants with White Blood Cells (WBC) count equal or less (≤) 10 × 10^9/LTime frame: 80 weeks
- Number of Participants with Hemoglobin (Hgb) equal or greater (≧) 10.0 g/dLTime frame: 80 weeks
- Number of Participants absence of major thrombotic eventsTime frame: 80 weeks
- Number of Participants with no progression to secondary acute myeloid leukemia (AML).Time frame: 80 weeks
- Number of Participants with no progression on the Total Symptom Score (TSS)Time frame: 80 weeks
Locations
73 sites in 9 countries. Site status is shown where the registry gives one.
USC Norris Comprehensive Cancer Center
Los Angeles, California
Georgetown University Medical Center
Washington D.C., District of Columbia
University of Kansas Medical Center (KUMC)
Kansas City, Kansas
American Oncology Partners of Maryland PA (Center for Cancer and Blood Disorders)
Bethesda, Maryland
Washington University School of Medicine
St Louis, Missouri
Weill Medical College of Cornell University
New York, New York
Stony Brook University Medical Center
Stony Brook, New York
Levine Cancer Institute
Charlotte, North Carolina
Duke University
Durham, North Carolina
Ohio State University
Columbus, Ohio
MD Anderson Cancer Center
Houston, Texas
Virginia Commonwealth University
Richmond, Virginia
University of Washington Medical Center - Fred Hutchinson Cancer Center
Seattle, Washington
St. Michael's Hospital
Toronto, Ontario, Canada
Princess Margaret Hospital
Toronto, Ontario, Canada
Jewish General Hospital
Montreal, Quebec, Canada
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China
Peking University People's Hospital
Beijing, Beijing Municipality, China
The Second Affiliated Hospital of AMU
Chongqing, Chongqing Municipality, China
Southern Hospital of Southern Medical University
Guangdong, Guangdong, China
Guangdong Provincial People's Hospital
Guangzhou, Guangzhou, China
Institute of Hematology and Oncology, Harbin The First Hospital
Harbin, Heilongjiang, China
Henan Cancer Hospital
Zhengzhou, Henan, China
Union Hospital Tong Ji Medical College
Wuhan, Hubei, China
Jiangsu Provincial Hospital
Nanjing, Jiangsu, China
The First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, China
Qilu Hospital of Shandong University
Jinan, Shandong, China
Ruijin Hospital, Shanghai Jiaotong University School of Medicine
Shanghai, Shanghai Municipality, China
Shanghai Sixth People's Hospital
Shanghai, Shanghai Municipality, China
West China Hospital, Sichuan University
Chengdu, Sichuan, China
Hematology Hospital of Chinese Academy of Medical Sciences
Tianjin, Tianjin Municipality, China
The First Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
Queen Mary Hospital
Hong Kong, Hong Kong, Hong Kong
Kameda General Hospital
Kamogawa, Chiba, Japan
Ehime University Hospital
Matsuyama, Ehime, Japan
Hiroshima Red Cross & Atomic-Bomb Survivors Hospital
Hiroshima, Hiroshima, Japan
Iwate Prefectural Central Hospital
Morioka, Iwate, Japan
Shonan Kamakura General Hospital
Kamakura, Kanagawa, Japan
Mie University Hospital
Tsu, Mie-ken, Japan
University of Miyazaki Hospital
Miyazaki, Miyazaki, Japan
Showing 40 of 73 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.